Edwards Lifesciences Corporation Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount
Edwards Lifesciences Corporation (EW) reported Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount of -$700.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-02-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount · last filed 2022-02-14
- Edwards Lifesciences Corporation equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2020-12-31 was -$1.40M.
- Edwards Lifesciences Corporation equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2020-09-30 was $0.00.
- Edwards Lifesciences Corporation equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2020-06-30 was $0.00.
- Edwards Lifesciences Corporation equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2020-03-31 was $700.00K.
- Edwards Lifesciences Corporation equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2020 was -$700.00K.
| Period end | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 3 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 6 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 9 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 12 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 12 month as first filed |
|---|---|---|---|---|---|
| 2020-12-31 | -$1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-14 | -$1.40M derived: sum of 2 quarters · filed 2022-02-14 | -$1.40M derived: sum of 3 quarters · filed 2022-02-14 | -$700.00K 10-K · filed 2022-02-14 | $700.00K 10-K · filed 2021-02-12 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-26 | $0.00 derived: sum of 2 quarters · filed 2020-10-26 | $700.00K 10-Q · filed 2020-10-26 | ||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-27 | $700.00K 10-Q · filed 2020-07-27 | |||
| 2020-03-31 | $700.00K 10-Q · filed 2020-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STERIS plc (STE) | Ireland | $20.343B | 25.49 |
| ZIMMER BIOMET HOLDINGS, INC. (ZBH) | United States | $17.103B | 20.66 |
| ALIGN TECHNOLOGY INC (ALGN) | United States | $10.346B | 29.06 |
| MSA Safety Inc (MSA) | United States | $7.023B | 21.47 |
| ESTABLISHMENT LABS HOLDINGS INC. (ESTA) | $1.954B | -65.76 | |
| Cadre Holdings, Inc. (CDRE) | United States | $1.123B | 33.88 |
| Enovis CORP (ENOV) | United States | $1.053B | -1.18 |
| Anteris Technologies Global Corp. (AVR) | United States | $0.746B | |
| Sanara MedTech Inc. (SMTI) | United States | $0.323B | -6.81 |
| Inogen Inc (INGN) | United States | $0.139B | -7.00 |